

## **XOFT TO PRESENT AT THE 26<sup>TH</sup> ANNUAL JP MORGAN HEALTHCARE CONFERENCE**

### **CEO to Provide Update on the Clinical and Commercial Adoption of the Axxent® Electronic Brachytherapy System**

**FREMONT, Calif., Jan. 3, 2008** – Xoft, Inc., developer of the Axxent® Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 26th Annual JP Morgan Healthcare Conference. Xoft president and CEO Michael Klein will present on Thursday, January 10, 2008, at 7:30am at The Westin St. Francis Hotel in San Francisco.

“We are excited to have the opportunity to provide an update on the adoption of this exciting new method of delivering internal radiation therapy since we went fully commercial in Q4 of 2007,” said Klein. “With breast cancer, the first FDA cleared indication for the Axxent System, we are already seeing excellent clinical results at the 10 initial clinical sites and more than a dozen commercial sites that have committed since we went commercial. Combined with strong awareness among the oncology community and the recent establishment of Medicare reimbursement for Electronic Brachytherapy in the hospital outpatient setting, we expect rapid and widespread commercial adoption, making it available to women who want to take advantage of breast conserving therapy.”

Cleared by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, the Axxent System is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings.

Use of the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the time required for radiation therapy for early stage breast cancer from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy. Effective July 2007, the CPT code for electronic brachytherapy is included in the AMA CPT 2008 codebook. Additionally, the Category III CPT Code 0182T: high dose rate electronic brachytherapy, per fraction, has been assigned a New Technology Ambulatory Payment Classification (APC). The APC payment applies to the outpatient hospital and ambulatory surgical settings, and includes the high dose rate electronic brachytherapy radiation treatment and the cost of the X-ray source.

**About Xoft, Inc.**

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent® Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

###

Axxent is a registered trademark of Xoft, Inc.

**Media Contacts:**

Chris K. Joseph

Xoft, Inc.

510/339-2293

[chris@ckjcomm.com](mailto:chris@ckjcomm.com)